Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06560762 · ClinicalTrials.gov registry record · Phase 1
Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
A Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Secretome Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT06560762: Recruiting Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF), sponsored by Secretome Therapeutics.
NCT06560762 is a Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF) that is actively recruiting participants, run by Secretome Therapeutics. The registered enrollment target is 12 participants, below the 218-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06560762, a Phase 1 study of Heart Failure With Preserved Ejection Fraction (HFPEF), is actively recruiting participants, sponsored by Secretome Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
A Phase 1, Open label, Multiple Ascending Dose Study to Assess Safety and Tolerability of STM-01 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
Conditions Studied
Interventions
- DRUG STM01
Study Locations (2)
Illinois
- Northwestern Medicine - Chicago
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2025-12-15 |
| Phase | Phase 1 |
What NCT06560762 shows while recruiting
NCT06560762 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 218-participant average among 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction (HFPEF) appearing as the primary indexed condition, and to 1 intervention - of which STM01 is the first listed.
NCT06560762 reports a single indexed study location in Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT06560762 about?
NCT06560762 is a clinical study titled "Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)". A Phase 1, Open label, Multiple Ascending Dose Study to Assess Safety and Tolerability of STM-01 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
What is the current status of trial NCT06560762?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-03-03. Estimated completion is 2025-12-15.
What conditions does trial NCT06560762 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction (HFPEF).
What interventions are being tested in trial NCT06560762?
The interventions under investigation include: STM01 (DRUG).
Who is sponsoring clinical trial NCT06560762?
This trial is sponsored by Secretome Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06560762 being conducted?
This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction (HFPEF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06560762's enrollment target sits among peer trials
12 10th of 9 the lowest of 9 other Heart Failure With Preserved Ejection Fraction (HFPEF) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction (HFPEF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · Phase 1
-
The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
RECRUITING
-
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
RECRUITING · Phase 4
-
The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
RECRUITING
-
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
RECRUITING
-
ELEVATE-HFpEF Clinical Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI